NO20092692L - MAPK/ERK kinaseinhibitorer - Google Patents

MAPK/ERK kinaseinhibitorer

Info

Publication number
NO20092692L
NO20092692L NO20092692A NO20092692A NO20092692L NO 20092692 L NO20092692 L NO 20092692L NO 20092692 A NO20092692 A NO 20092692A NO 20092692 A NO20092692 A NO 20092692A NO 20092692 L NO20092692 L NO 20092692L
Authority
NO
Norway
Prior art keywords
mapk
kinase inhibitors
erk kinase
compounds
erk
Prior art date
Application number
NO20092692A
Other languages
English (en)
Other versions
NO342270B1 (no
Inventor
Stephen W Kaldor
Michael B Wallace
Qing Dong
Xianchang Gong
Nicholas Scorah
Toufike Kanouni
Feng Zhou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20092692L publication Critical patent/NO20092692L/no
Publication of NO342270B1 publication Critical patent/NO342270B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Forbindelse med følgende formel er tilveiebrakt for anvendelse med MEK: hvori variablene er som definert heri. Også tilveiebrakt er farmasøytiske sammensetninger, kitt og fremstilte artikler som innbefatter slike forbindelser; fremgangsmåter og intermediater anvendelige for fremstilling av forbindelsene; og fremgangsmåter for anvendelse av nevnte forbindelser.
NO20092692A 2006-12-20 2009-07-15 MAPK/ERK-kinaseinhibitorer, farmasøytiske sammensetninger inneholdende slike og anvendelse NO342270B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87091306P 2006-12-20 2006-12-20
PCT/US2007/087913 WO2008079814A2 (en) 2006-12-20 2007-12-18 Mapk/erk kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20092692L true NO20092692L (no) 2009-09-16
NO342270B1 NO342270B1 (no) 2018-04-30

Family

ID=39462025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092692A NO342270B1 (no) 2006-12-20 2009-07-15 MAPK/ERK-kinaseinhibitorer, farmasøytiske sammensetninger inneholdende slike og anvendelse

Country Status (35)

Country Link
US (4) US8030317B2 (no)
EP (1) EP2125810B1 (no)
JP (1) JP5513127B2 (no)
KR (1) KR101488467B1 (no)
CN (1) CN101679411B (no)
AR (1) AR064640A1 (no)
AU (1) AU2007337003B2 (no)
BR (1) BRPI0720525B8 (no)
CA (1) CA2673647C (no)
CL (1) CL2007003742A1 (no)
CO (1) CO6230984A2 (no)
CR (1) CR10937A (no)
DK (1) DK2125810T3 (no)
EA (1) EA016312B1 (no)
EC (1) ECSP099529A (no)
ES (1) ES2430966T3 (no)
GE (1) GEP20125511B (no)
HR (1) HRP20130684T1 (no)
IL (1) IL199362A (no)
JO (1) JO2985B1 (no)
MA (1) MA31151B1 (no)
MX (1) MX2009006675A (no)
MY (1) MY157871A (no)
NO (1) NO342270B1 (no)
NZ (1) NZ578310A (no)
PE (1) PE20090071A1 (no)
PL (1) PL2125810T3 (no)
PT (1) PT2125810E (no)
RS (1) RS52887B (no)
SI (1) SI2125810T1 (no)
TN (1) TN2009000249A1 (no)
TW (1) TWI396538B (no)
UA (1) UA98479C2 (no)
WO (1) WO2008079814A2 (no)
ZA (1) ZA200904682B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790649A1 (en) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
JP5249939B2 (ja) * 2006-10-23 2013-07-31 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
US8063066B2 (en) * 2007-03-19 2011-11-22 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
CA2705452C (en) * 2007-11-12 2016-05-31 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CA2742785A1 (en) * 2008-11-18 2010-05-27 Takeda Pharmaceutical Company Limited Process for making (r) -3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-flouro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3h,8h)-dione and intermediates thereof
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
UY34114A (es) 2011-06-03 2013-01-03 Millennium Pharm Inc Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
SG11201405356QA (en) 2012-03-01 2014-11-27 Array Biopharma Inc Serine/threonine kinase inhibitors
WO2013144923A1 (en) 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
WO2015192761A1 (zh) * 2014-06-17 2015-12-23 辰欣药业股份有限公司 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
CN111201225B (zh) * 2017-06-23 2021-11-05 基石药业 作为mek抑制剂的类香豆素环类化合物及其应用
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
US20220144819A1 (en) 2018-11-20 2022-05-12 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
TWI825637B (zh) * 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117779203B (zh) * 2024-02-28 2024-05-31 西北工业大学 一种n-苄基-2-甲基-4-硝基苯胺单晶及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EP1144385B1 (en) 1999-01-13 2005-08-17 Warner-Lambert Company Llc Benzoheterocycles and their use as mek inhibitors
WO2001055147A1 (en) 2000-01-25 2001-08-02 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
BRPI0112584B8 (pt) 2000-07-19 2021-05-25 Warner Lambert Co ésteres oxigenados de derivados de ácido benzidroxâmico de 4-iodofenilamino, composição farmacêutica e combinação
NZ524806A (en) 2000-10-23 2006-03-31 Smithkline Beecham Corp Tri-substituted 8H-pyrido[2,3-d]pyrimidin-7-one compounds
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
EP1482932B1 (en) 2002-03-13 2009-11-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
AU2003220202A1 (en) 2002-03-13 2003-09-29 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
RU2330851C9 (ru) * 2003-05-23 2008-10-20 Центарис Гмбх ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ НАРУШЕНИЯ, КОТОРЫЕ ОБУСЛОВЛЕНЫ НЕПРАВИЛЬНО НАПРАВЛЕННЫМИ ПРОЦЕССАМИ КЛЕТОЧНОЙ СИГНАЛЬНОЙ ТРАНСДУКЦИИ, СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
WO2005002351A2 (en) 2003-07-03 2005-01-13 Sunghag Koo Ferment ginseng oil
MXPA06000921A (es) 2003-07-24 2006-03-30 Warner Lambert Co Derivados de benzamidazoles como inhibidores de mek.
WO2005011597A2 (en) 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
US7485643B2 (en) 2003-11-19 2009-02-03 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
CN101912400B (zh) 2004-06-11 2013-06-26 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
ATE443063T1 (de) 2004-12-01 2009-10-15 Merck Serono Sa Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
JP5249939B2 (ja) * 2006-10-23 2013-07-31 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
WO2008055842A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
CA2705452C (en) * 2007-11-12 2016-05-31 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CA2742785A1 (en) 2008-11-18 2010-05-27 Takeda Pharmaceutical Company Limited Process for making (r) -3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-flouro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3h,8h)-dione and intermediates thereof

Also Published As

Publication number Publication date
RS52887B (en) 2014-02-28
JO2985B1 (ar) 2016-09-05
UA98479C2 (en) 2012-05-25
PE20090071A1 (es) 2009-04-04
PT2125810E (pt) 2013-07-29
JP2010514680A (ja) 2010-05-06
CN101679411A (zh) 2010-03-24
US8030317B2 (en) 2011-10-04
JP5513127B2 (ja) 2014-06-04
TW200835496A (en) 2008-09-01
BRPI0720525A2 (pt) 2014-01-07
MA31151B1 (fr) 2010-02-01
AU2007337003A1 (en) 2008-07-03
AR064640A1 (es) 2009-04-15
CL2007003742A1 (es) 2008-06-13
TN2009000249A1 (en) 2010-10-18
TWI396538B (zh) 2013-05-21
AU2007337003B2 (en) 2013-05-02
NZ578310A (en) 2012-01-12
EA200970605A1 (ru) 2009-12-30
ES2430966T3 (es) 2013-11-22
PL2125810T3 (pl) 2013-09-30
US8293901B2 (en) 2012-10-23
KR20090091353A (ko) 2009-08-27
CA2673647A1 (en) 2008-07-03
US20080255160A1 (en) 2008-10-16
MX2009006675A (es) 2009-08-12
US20120202999A1 (en) 2012-08-09
WO2008079814A2 (en) 2008-07-03
EA016312B1 (ru) 2012-04-30
BRPI0720525B8 (pt) 2021-05-25
CR10937A (es) 2009-11-20
CN101679411B (zh) 2013-04-17
HRP20130684T1 (en) 2013-10-11
AU2007337003A2 (en) 2009-07-30
EP2125810B1 (en) 2013-04-24
CO6230984A2 (es) 2010-12-20
MY157871A (en) 2016-07-29
IL199362A (en) 2013-07-31
CA2673647C (en) 2016-02-09
KR101488467B1 (ko) 2015-01-30
US20100130518A1 (en) 2010-05-27
EP2125810A2 (en) 2009-12-02
NO342270B1 (no) 2018-04-30
US8470837B2 (en) 2013-06-25
SI2125810T1 (sl) 2013-09-30
WO2008079814A3 (en) 2008-09-04
GEP20125511B (en) 2012-05-10
ECSP099529A (es) 2009-08-28
DK2125810T3 (da) 2013-07-29
BRPI0720525B1 (pt) 2020-03-03
US20110065733A1 (en) 2011-03-17
ZA200904682B (en) 2010-09-29

Similar Documents

Publication Publication Date Title
NO20092692L (no) MAPK/ERK kinaseinhibitorer
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
TN2010000131A1 (en) Polo-like kinase inhibitors
WO2008115890A3 (en) Mapk/erk kinase inhibitors
MY150542A (en) Cmet inhibitors
WO2008079787A3 (en) Glucokinase activators
WO2010008847A3 (en) Pi3k/m tor inhibitors
ATE479687T1 (de) Kinaseinhibitoren
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EA200800321A1 (ru) Ингибиторы гистондеацетилазы
WO2008116107A3 (en) Piperazine derivatives as glucokinase activators
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
NO20081684L (no) En forbedret fremgangsmate for fremstilling av okazolidin-beskyttende aminodiolforbindelser anvendbare som mellomprodukter for Florfenicol
WO2008054956A3 (en) Kinase inhibitors
NO20076345L (no) Bisykliske derivater som P38-kinaseinhibitorer
NO20091999L (no) MAPK/ERK kinase inhibitorer
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
WO2009129401A8 (en) Kinase inhibitors
WO2008045834A3 (en) Kinase inhibitors
SE0403085D0 (sv) Novel componds